Literature DB >> 12900003

The new World Health Organization/International Society of Urological Pathology (WHO/ISUP) classification for TA, T1 bladder tumors: is it an improvement?

Jonathan I Epstein1.   

Abstract

The World Health Organization/International Society of Urological Pathology (WHO/ISUP) consensus classification of urothelial neoplasms of the urinary bladder was developed in an attempt to both improve upon prior classification systems as well as to adopt a classification system that would have widespread acceptance. Prior to this classification system, numerous diverse grading schemes for bladder cancer existed whereby the same lesion seen by different pathologists would result in very different diagnoses solely based on definitional differences of lesions. Another strength of the consensus classification system is that it provides detailed histological criteria for papillary urothelial lesions. In contrast, prior grading systems for bladder tumors were vague and subjective. The current classification system allows for designation of a lesion (papillary urothelial neoplasm of low malignant potential), which biologically has a very low risk of progression, yet is not entirely benign. In the past, these lesions were a source of controversy, as some experts in the field required very restrictive criteria for the diagnosis of papilloma and would label such lesions as malignant. Other experts in the field, not wanting to label a patient with such a low-grade papillary lesion as having carcinoma, would diagnose these lesions as papilloma. This intermediate category allows both schools of thought to diagnose a lesion as not fully malignant, yet still documents need for additional follow-up. Since its inception, several studies have been published documenting the relationship of tumors classified using the WHO/ISUP system to prognosis. These articles are summarized within this review.

Entities:  

Mesh:

Year:  2003        PMID: 12900003     DOI: 10.1016/s1040-8428(03)00073-8

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  15 in total

1.  Reproductibilité des classifications OMS 1973 et OMS 2004 des tumeurs urothéliales papillaires de la vessie.

Authors:  Soumaya Ben Abdelkrim; Soumaya Rammeh; Amel Trabelsi; Lilia Ben Yacoub-Abid; Nabil Ben Sorba; Lilia Jaïdane; Moncef Mokni
Journal:  Can Urol Assoc J       Date:  2011-09-08       Impact factor: 1.862

2.  A nuclear grading system is a strong predictor of survival in epitheloid diffuse malignant pleural mesothelioma.

Authors:  Kyuichi Kadota; Kei Suzuki; Christos Colovos; Camelia S Sima; Valerie W Rusch; William D Travis; Prasad S Adusumilli
Journal:  Mod Pathol       Date:  2011-10-07       Impact factor: 7.842

3.  Histologic grading of urothelial papillary neoplasms: impact of combined grading (two-numbered grading system) on reproducibility.

Authors:  Burçin Tuna; Kutsal Yörükoglu; Ender Düzcan; Sait Sen; Nalan Nese; Banu Sarsık; Aysegul Akder; Sehnaz Sayhan; Uğur Mungan; Ziya Kirkali
Journal:  Virchows Arch       Date:  2011-04-12       Impact factor: 4.064

4.  Surveillance guidelines based on recurrence patterns for upper tract urothelial carcinoma.

Authors:  Jennifer A Locke; Reza Hamidizadeh; Wassim Kassouf; Ricardo A Rendon; David Bell; Jonathan Izawa; Joseph Chin; Anil Kapoor; Bobby Shayegen; Jean-Baptiste Lattouf; Fred Saad; Louis Lacombe; Yves Fradet; Adrien S Fairey; Niels-Eric Jacobson; Darrel E Drachenberg; Ilias Cagiannos; Alan I So; Peter C Black
Journal:  Can Urol Assoc J       Date:  2018-04-12       Impact factor: 1.862

5.  Diagnostic performance of diffusion-weighted magnetic resonance imaging in bladder cancer: potential utility of apparent diffusion coefficient values as a biomarker to predict clinical aggressiveness.

Authors:  Shuichiro Kobayashi; Fumitaka Koga; Soichiro Yoshida; Hitoshi Masuda; Chikako Ishii; Hiroshi Tanaka; Yoshinobu Komai; Minato Yokoyama; Kazutaka Saito; Yasuhisa Fujii; Satoru Kawakami; Kazunori Kihara
Journal:  Eur Radiol       Date:  2011-06-18       Impact factor: 5.315

Review 6.  Update for the practicing pathologist: The International Consultation On Urologic Disease-European association of urology consultation on bladder cancer.

Authors:  Mahul B Amin; Steven C Smith; Victor E Reuter; Jonathan I Epstein; David J Grignon; Donna E Hansel; Oscar Lin; Jesse K McKenney; Rodolfo Montironi; Gladell P Paner; Hikmat A Al-Ahmadie; Ferran Algaba; Syed Ali; Isabel Alvarado-Cabrero; Lukas Bubendorf; Liang Cheng; John C Cheville; Glen Kristiansen; Richard J Cote; Brett Delahunt; John N Eble; Elizabeth M Genega; Christian Gulmann; Arndt Hartmann; Cord Langner; Antonio Lopez-Beltran; Cristina Magi-Galluzzi; Jorda Merce; George J Netto; Esther Oliva; Priya Rao; Jae Y Ro; John R Srigley; Satish K Tickoo; Toyonori Tsuzuki; Saleem A Umar; Theo Van der Kwast; Robert H Young; Mark S Soloway
Journal:  Mod Pathol       Date:  2014-11-21       Impact factor: 7.842

7.  Bladder cancer collaborative stage variables and their data quality, usage, and clinical implications: a review of SEER data, 2004-2010.

Authors:  Mary E Charlton; Margaret Peggy Adamo; Leon Sun; Sundeep Deorah
Journal:  Cancer       Date:  2014-12-01       Impact factor: 6.860

8.  Tumour Behaviour of Low-Grade Papillary Urothelial Carcinoma: A Single-Centre Retrospective Study.

Authors:  Satya Dutta; Biswajit Dey; Vandana Raphael; Yookarin Khonglah; Jaya Mishra; Evarisalin Marbaniang; Pranjal Kalita; Stephen Sailo
Journal:  Cureus       Date:  2021-06-29

9.  Mixed low- and high-grade papillary urothelial carcinoma: histopathogenetic and clinical significance.

Authors:  Kien T Mai; Trevor A Flood; Phillip Williams; Zuzana Kos; Eric C Belanger
Journal:  Virchows Arch       Date:  2013-08-04       Impact factor: 4.064

10.  Comprehensive pathological analyses in lung squamous cell carcinoma: single cell invasion, nuclear diameter, and tumor budding are independent prognostic factors for worse outcomes.

Authors:  Kyuichi Kadota; Jun-Ichi Nitadori; Kaitlin M Woo; Camelia S Sima; David J Finley; Valerie W Rusch; Prasad S Adusumilli; William D Travis
Journal:  J Thorac Oncol       Date:  2014-08       Impact factor: 15.609

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.